Surrey Heartlands

Joint Formulary & PAD

Insulin glulisine - Apidra - Diabetes Mellitus

You are here : Home > Formulary Search > Insulin glulisine - Apidra - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Cartridges
  • Pre-filled pen
  • Vials
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Prescribe by brand and state form. SASH - restricted to diabetes team initiation only.

Documentation

Guidelines (Local)
SDCCG - Insulin initiation in Type 2 Diabetes Guidelines - Sep 2014
Safety Information
Cutaneous amyloidosis - MHRA alert - guidance for healthcare professionals - Dec 2020

PAD Profile

ChemicalSubstance :
Insulin glulisine - Apidra
Indication :
Diabetes Mellitus
Group Name :
Insulin
Keywords :
short-acting insulins, short acting insulins, lipohypertrophy, cutaneous amyloidosis
Brand Names Include :
Apidra, ClikSTAR, Autopen, Apidra SoloStar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Diabetes Mellitus
Supporting Documents :
2

Other Indications

Below are listed other indications that Insulin glulisine - Apidra is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.

Committee Recommendations (2)

14 Jul 21 - Surrey Heartlands Medicines Safety Committee (MSC)

MHRA Safety Alert

Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site.  Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.

Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below

01 Jul 15 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
This drug has been agreed as appropriate for initiation in Primary Care and/or continued in Primary Care following a recommendation from specialists in other health care sectors. Following consideration by the PCN, it has been assigned a GREEN traffic light status.